|
Poster
53 |
Patient-derived in vitro models serve as a preclinical test system for personalized therapy and drug development in an animal-free setup |
When studying neurobiological or oncologic mechanisms, the lack of available relevant human tissue hampers efficient preclinical research and drug development. Currently, various human cellular test system have been developed to improve fundamental research, drug development, translational research, and clinical application for preclinical testing and to replace animal models by patient-derived model systems.
Here, we present two approaches for patient-derived model systems that offer new possibilities to study compound safety, toxicology and efficacy in relevant human model systems.
The use of patient-derived induced pluripotent stem cells (iPSC) allows to model a variety of human pathologies by analyzing disease- and patient-specific key cell types in vitro, while always retaining the individual genetic background of the affected donor. By this, also communication and interaction of two or more cell types can be studied easily in a two- or three-dimensional setting.
3D patient-derived tumor models enable early drug screening, drug development and preclinical efficacy drug testing in vitro. By establishing 3D autologous tumor-immune cell co-cultures, immune activation profiling and drug efficacy testing can be performed to make response predictions to immunotherapies in preclinical setting.